Abstract
More than twenty years ago Rinderknecht et al. identified a minor trypsin isoform resistant to natural trypsin inhibitors in the human pancreatic juice. At the same time, Estell and Laskowski found that an inhibitor-resistant trypsin from the pyloric caeca of the starfish, Dermasterias imbricata rapidly hydrolyzed the reactive-site peptide bonds of trypsin inhibitors. A connection between these two seminal discoveries was made recently, when human mesotrypsin was shown to cleave the reactive-site peptide bond of the Kunitz-type soybean trypsin inhibitor, and degrade the Kazal-type pancreatic secretory trypsin inhibitor. These observations indicate that proteases specialized for the degradation of protease inhibitors are ubiquitous in metazoa, and prompt new investigations into their biological significance. Here we review the history and properties of human mesotrypsin, and discuss its function in the digestive degradation of dietary trypsin inhibitors and possible pathophysiological role in pancreatitis.
Keywords: trypsinogen, proteomics, t cell receptor genes, mesotrypsin, polypeptide inhibitors, enteropeptidase, duodenum
Protein & Peptide Letters
Title: Human Mesotrypsin Defies Natural Trypsin Inhibitors: From Passive Resistance to Active Destruction.
Volume: 12 Issue: 5
Author(s): Miklos Sahin-Toth
Affiliation:
Keywords: trypsinogen, proteomics, t cell receptor genes, mesotrypsin, polypeptide inhibitors, enteropeptidase, duodenum
Abstract: More than twenty years ago Rinderknecht et al. identified a minor trypsin isoform resistant to natural trypsin inhibitors in the human pancreatic juice. At the same time, Estell and Laskowski found that an inhibitor-resistant trypsin from the pyloric caeca of the starfish, Dermasterias imbricata rapidly hydrolyzed the reactive-site peptide bonds of trypsin inhibitors. A connection between these two seminal discoveries was made recently, when human mesotrypsin was shown to cleave the reactive-site peptide bond of the Kunitz-type soybean trypsin inhibitor, and degrade the Kazal-type pancreatic secretory trypsin inhibitor. These observations indicate that proteases specialized for the degradation of protease inhibitors are ubiquitous in metazoa, and prompt new investigations into their biological significance. Here we review the history and properties of human mesotrypsin, and discuss its function in the digestive degradation of dietary trypsin inhibitors and possible pathophysiological role in pancreatitis.
Export Options
About this article
Cite this article as:
Sahin-Toth Miklos, Human Mesotrypsin Defies Natural Trypsin Inhibitors: From Passive Resistance to Active Destruction., Protein & Peptide Letters 2005; 12 (5) . https://dx.doi.org/10.2174/0929866054395356
DOI https://dx.doi.org/10.2174/0929866054395356 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Lumiflavin Enhances the Effects of Ionising Radiation on Ovarian Cancer Stem-Like Cells by Inhibiting Autophagy
Anti-Cancer Agents in Medicinal Chemistry Peptides in Oral Diseases
Current Pharmaceutical Design The Role of the PERK/eIF2α/ATF4/CHOP Signaling Pathway in Tumor Progression During Endoplasmic Reticulum Stress
Current Molecular Medicine Novel PET Tracers in the Management of Cardiac Sarcoidosis
Current Radiopharmaceuticals Molecular Characterization of Upper Tract Urothelial Carcinoma for Precision Therapeutics and Non-invasive Diagnostics
Current Genomics Analytical Methods for the Identification of Pigments in Tattoo Inks and Some of Their Physiological Side Effects: A Review
Current Pharmaceutical Analysis Targeted Drug Delivery Systems and Their Therapeutic Applications in Cancer and Immune Pathological Conditions
Infectious Disorders - Drug Targets microRNA, Cancer and Cancer Chemoprevention
Current Molecular Pharmacology Expression of Defensins in Gingiva and Their Role in Periodontal Health and Disease
Current Pharmaceutical Design 1,5-Diaryl-3-oxo-1,4-pentadienes: A Case for Antineoplastics with Multiple Targets
Current Medicinal Chemistry Tribbles-Related Protein Family Members as Regulators or Substrates of the Ubiquitin-Proteasome System in Cancer Development
Current Cancer Drug Targets Microsatellite Instability (MSI) as Genomic Marker in Endometrial Cancer: Toward Scientific Evidences
Mini-Reviews in Medicinal Chemistry Mechanism-based Combinations with Pim Kinase Inhibitors in Cancer Treatments
Current Pharmaceutical Design The Anticancer Properties of Dietary Polyphenols and its Relation with Apoptosis
Current Pharmaceutical Design Impact of Oncogenic Protein Tyrosine Phosphatases in Cancer
Anti-Cancer Agents in Medicinal Chemistry Anti-Cancer Potential of a Novel SERM Ormeloxifene
Current Medicinal Chemistry Periodontal Disease and Potential Association with Systemic Diseases and Conditions (Mini-review)
Applied Clinical Research, Clinical Trials and Regulatory Affairs Targeting p73 - a Potential Approach in Cancer Treatment
Current Pharmaceutical Design The Potential of Oxidative Stress Related Genes as Prognostic Biomarkers in Head and Neck Squamous Cell Carcinoma
Combinatorial Chemistry & High Throughput Screening Targeting the Perpetrator: Breast Cancer Stem Cell Therapeutics
Current Drug Targets